BR112018073688A2 - método de tratamento de hiperglicemia - Google Patents

método de tratamento de hiperglicemia

Info

Publication number
BR112018073688A2
BR112018073688A2 BR112018073688-0A BR112018073688A BR112018073688A2 BR 112018073688 A2 BR112018073688 A2 BR 112018073688A2 BR 112018073688 A BR112018073688 A BR 112018073688A BR 112018073688 A2 BR112018073688 A2 BR 112018073688A2
Authority
BR
Brazil
Prior art keywords
hyperglycemia
disorders
treatment method
conditions
diabetes
Prior art date
Application number
BR112018073688-0A
Other languages
English (en)
Inventor
Hsu Jui-Pao
Shane Guang-Tzuu
Lee Meng-Ju
liao Yi-ping
YEH Yu-Yin
Original Assignee
Center Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Center Laboratories, Inc. filed Critical Center Laboratories, Inc.
Publication of BR112018073688A2 publication Critical patent/BR112018073688A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

são divulgados métodos para o tratamento de condições e/ou distúrbios relacionados com hiperglicemia. tais condições e/ou distúrbios relacionados à hiperglicemia incluem, mas não estão limitados a diabetes mellitus tipo ii, tipo ii, diabetes gestacional, outras formas de diabetes e distúrbios relacionados a eles. em particular, a presente invenção refere-se a métodos de utilização de (r)-(+)-verapamil ou seu sal farmaceuticamente aceitável no tratamento de condições e/ou distúrbios relacionados com hiperglicemia.
BR112018073688-0A 2016-05-20 2017-05-17 método de tratamento de hiperglicemia BR112018073688A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662339131P 2016-05-20 2016-05-20
US62/339,131 2016-05-20
PCT/CN2017/084746 WO2017198177A1 (en) 2016-05-20 2017-05-17 Method of treating hyperglycemia

Publications (1)

Publication Number Publication Date
BR112018073688A2 true BR112018073688A2 (pt) 2019-02-26

Family

ID=60326464

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018073688-0A BR112018073688A2 (pt) 2016-05-20 2017-05-17 método de tratamento de hiperglicemia

Country Status (15)

Country Link
US (2) US9980935B2 (pt)
EP (1) EP3413886A4 (pt)
JP (3) JP6692903B2 (pt)
KR (3) KR102423967B1 (pt)
CN (2) CN113384571A (pt)
AU (1) AU2017267006B2 (pt)
BR (1) BR112018073688A2 (pt)
CA (2) CA3003319C (pt)
HK (1) HK1254471A1 (pt)
IL (1) IL262994B2 (pt)
MX (1) MX2018013943A (pt)
RU (2) RU2739255C2 (pt)
SG (1) SG11201809899RA (pt)
TW (1) TWI659738B (pt)
WO (1) WO2017198177A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113384571A (zh) * 2016-05-20 2021-09-14 晟德大药厂股份有限公司 (r)-(+)-维拉帕米用于治疗高血糖的用途及其药学组合物
US10639292B2 (en) 2018-04-20 2020-05-05 Center Laboratories, Inc. Method of treating hyperglycemia
EP3981401A1 (en) * 2020-10-06 2022-04-13 InSphero AG Pharmaceutical combination for the treatment and/or prevention of diabetes comprising a calcium channel blocking agent and an incretin mimetic
CN117241798A (zh) * 2021-04-29 2023-12-15 日东制药股份有限公司 包括gpr40促进剂以及sglt-2抑制物的医药组成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616549D0 (en) * 1996-08-06 1996-09-25 Chiroscience Ltd Therapeutic product and its use
US20030092765A1 (en) * 2001-11-15 2003-05-15 John Kelly Treatment of abnormal increases in gastrointestinal motility with (R)-verapamil
ES2390231T3 (es) * 2005-06-03 2012-11-07 Mitsubishi Tanabe Pharma Corporation Agentes farmacéuticos concomitantes y su uso
RU2338521C1 (ru) * 2007-02-28 2008-11-20 Илья Николаевич Медведев Способ быстрого снижения активности тромбопластиногенерации у лиц с метаболическим синдромом
CA2755068C (en) * 2009-03-12 2018-11-06 Nordic Bioscience A/S Treatment of diabetes and metabolic syndrome
CN101869708A (zh) * 2009-04-24 2010-10-27 北京奥萨医药研究中心有限公司 含有钙通道阻滞剂和双胍类降糖药物的药物组合物及其用途
WO2010138535A1 (en) * 2009-05-27 2010-12-02 Bristol-Myers Squibb Company Methods for treating type 2 diabetes in patients resistant to previous treatment with other anti-diabetic drugs employing an sglt2 inhibitor and compositions thereof
TWI410630B (zh) * 2009-11-10 2013-10-01 Ct Lab Inc 一種用以治療與食慾素受體１、食慾素受體２、體抑素受體２或多巴胺ｄ２ｌ受體相關之疾病的方法和組合物
AU2010319438B2 (en) * 2009-11-13 2015-05-21 Astrazeneca Uk Limited Reduced mass metformin formulations
EP2573088A1 (en) * 2011-09-26 2013-03-27 Prous Institute for Biomedical Research, S.A. Pyrano[3,2-c]benzopyran-6(2h)-one derivatives and uses thereof
US10314851B2 (en) * 2014-03-17 2019-06-11 Massachusetts Institute Of Technology Metakaryocidal treatments
CA2964177A1 (en) * 2014-10-29 2016-05-06 Center Laboratories, Inc. Crystal forms of verapamil hydrochloride
CN113384571A (zh) * 2016-05-20 2021-09-14 晟德大药厂股份有限公司 (r)-(+)-维拉帕米用于治疗高血糖的用途及其药学组合物

Also Published As

Publication number Publication date
AU2017267006A1 (en) 2018-05-10
EP3413886A1 (en) 2018-12-19
US9980935B2 (en) 2018-05-29
RU2018139578A (ru) 2020-06-22
KR20210000757A (ko) 2021-01-05
US20180235921A1 (en) 2018-08-23
TWI659738B (zh) 2019-05-21
JP2019503983A (ja) 2019-02-14
IL262994A (en) 2018-12-31
RU2020140694A3 (pt) 2021-10-08
US20170333382A1 (en) 2017-11-23
CA3114057A1 (en) 2017-11-23
MX2018013943A (es) 2019-03-28
CN113384571A (zh) 2021-09-14
KR20210121305A (ko) 2021-10-07
AU2017267006B2 (en) 2019-07-11
CN108430467A (zh) 2018-08-21
CA3003319A1 (en) 2017-11-23
EP3413886A4 (en) 2019-09-18
RU2739255C2 (ru) 2020-12-22
KR102200664B1 (ko) 2021-01-08
TW201740933A (zh) 2017-12-01
JP2020100651A (ja) 2020-07-02
KR102423967B1 (ko) 2022-07-21
JP6692903B2 (ja) 2020-05-13
JP7266327B2 (ja) 2023-04-28
SG11201809899RA (en) 2018-12-28
RU2018139578A3 (pt) 2020-06-22
RU2020140694A (ru) 2021-01-25
IL262994B1 (en) 2023-03-01
CN108430467B (zh) 2021-06-22
JP2022050572A (ja) 2022-03-30
KR20180058816A (ko) 2018-06-01
CA3003319C (en) 2021-05-25
HK1254471A1 (zh) 2019-07-19
US10278943B2 (en) 2019-05-07
WO2017198177A1 (en) 2017-11-23
IL262994B2 (en) 2023-07-01

Similar Documents

Publication Publication Date Title
BR112018003985A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112018073688A2 (pt) método de tratamento de hiperglicemia
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
BR112017008659A2 (pt) ?métodos e compostos de agonista de gip?
BR112017006940A2 (pt) triazolopirazinonas como inibidores de pde1
BR112014018592A2 (pt) composição e método para o diagnóstico e tratamento de doenças associadas à degeneração de neuritos
PH12017500493A1 (en) Combination therapy
BR112020003865A8 (pt) Composições farmacêuticas compreendendo sepiapterina e seus usos
JOP20170004B1 (ar) الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
BR112019003579A2 (pt) Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos
BR112015022041A2 (pt) derivados substituídos de 3-fenilpropilamina para o tratamento de doenças e distúrbios oftálmicas
BR112017007063A2 (pt) ?composições e métodos para o tratamento de insônia?
BR112019002730A2 (pt) acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa
BR112017010440A2 (pt) administração sublingual de riluzol
BR112019008384A2 (pt) composição farmacêutica, processos para tratamento e seus usos
WO2016097315A3 (en) Blood brain barrier transport molecules and uses thereof
MY187564A (en) Treatment of dementia
GT201600250A (es) Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncer
BR112017006342A2 (pt) composto de sal de ácido benzenossulfônico, forma em estado sólido cristalino, composição farmacêutica, produto farmacêutico de combinação, método de tratamento de doenças ou condições, uso de um composto de sal de ácido benzenossulfônico, e, processo para preparação de um composto de sal de ácido benzenossulfônico.
BR112018011851A2 (pt) compostos de isoindol
BR112019011462A2 (pt) peptídeo coagonista de gip/glp-1, e, peptídeo para uso no tratamento e/ou profilaxia da doença de alzheimer clínica.
WO2015026494A3 (en) Methods for treating tissue fibrosis
BR112015022907A8 (pt) formas cristalinas de sal de (2-(2-(4-fluorfenil) tiazol-4-il) propan-2-il) carbamato de (s)-quinuclidin-3-ila e seus usos
BR112018017077A2 (pt) terapias de combinação para tratamento de atrofia muscular espinhal
BR112018009745A2 (pt) compostos heterocíclicos para o tratamento de doença

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.